September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
July 2025 in “Journal of the European Academy of Dermatology and Venereology” 1 citations
,
August 2023 in “Journal of Cutaneous Medicine and Surgery” Anthralin 0.2% is effective for hair regrowth in children with alopecia areata.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
10 citations
,
March 2023 in “Journal of Managed Care & Specialty Pharmacy” Alopecia areata and atopic dermatitis have similar healthcare costs, but alopecia areata leads to more outpatient and long-term disability expenses.
January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
May 2025 in “Journal of Nanobiotechnology” The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
August 2019 in “Reactions Weekly” Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
August 2019 in “Carolina Digital Repository (University of North Carolina at Chapel Hill)” DHT enhances androgen receptor activity more than testosterone, and MAGE-11 influences this activity through specific interactions.